Escaping cell death: Survival proteins in cancer

Experimental Cell Research

Volumn 248, Issue 1, 1999, Pages 30-43

  Jäättelä, Marja ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Apoptosis; Bcl 2; Cancer; Heat shock protein; Survivin

Indexed keywords

HEAT SHOCK PROTEIN; PROTEIN BCL 2;

ANIMAL CELL; CANCER GRADING; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL DEATH; CELL SURVIVAL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0038668000     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4455     Document Type: Article

References (189)

1. Ashkenazi A., Dixit V. M. Death receptors: Signaling and Modulation. Science. 281:1998;1305-1308.
2. Green D. R., Reed J. C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
3. Evan G., Littlewood T. A matter of life and cell death. Science. 281:1998;1317-1322.
4. Thornberry N. A., Lazebnik Y. Caspases: Enemies within. Science. 281:1998;1312-1316.
5. Boldin M. P., Goncharov T. M., Goltsev Y. V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell. 85:1996;803-815.
6. Muzio M., Chinnaiyan A. M., Kischkel F. C., O'Rourke K., Shevchenko A., Ni J., Scaffidi C., Bretz J. D., Zhang M., Gentz R., Mann M., Krammer P. H., Peter M. E., Dixit V. M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 85:1996;817-827.
7. Li P., Nijhawan D., Budihardjo I., Srinivasula S. M., Ahmad M., Alnemeri E. S., Wang X. Cytochromec. Cell. 91:1997;479-489.
8. Zou H., Henzel W. I., Liu X., Lutschg A., Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochromec. Cell. 90:1997;405-413.
9. Adams J. M., Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science. 281:1998;1322-1326.
10. LaCasse E. C., Baird S., Korneluk R. G., MacKenzie A. E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 17:1998;3247-3259.
11. Jäättelä M., Wissing D., Bauer P. A., Li G. C. Major heat shock protein hsp70 protects tumor cells from tumor necrosis factor cytotoxicity. EMBO J. 11:1992;3507-3512.
12. Mosser D. D., Caron A. W., Bourget L., Denis-Larose C., Massie B. Role of human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol. Cell. Biol. 17:1997;5317-5327.
13. Jäättelä M., Wissing D., Kokholm K., Kallunki T., Egeblad M. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J. 17:1998;6124-6134.
14. Mehlen P., Schulze-Osthoff K., Arrigo A.-P. Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/APO-1 and staurosporine-induced cell death. J. Biol. Chem. 271:1996;16510-16514.
15. Garrido C., Ottavi P., Fromentin A., Hammann A., Arrigo A.-P., Chauffert B., Mehlen P. HSP27 is a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res. 57:1997;2661-2667.
16. Tsujimoto Y., Cossman J., Jaffe E., Croce C. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 228:1985;1440-1443.
17. Vaux D. L., Cory S., Adams J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:1988;440-442.
18. McDonnell T. J., Deane N., Platt F. M., Numez G., Jaeger U., McKearn J. P., Korsmeyer S. J. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 57:1989;79-88.
19. Strasser A., Harris A. W., Bath M. L., Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 348:1990;331-333.
20. Hockenbery D., Nuñez G., Milliman C., Screiber R. D., Korsmeyer S. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:1990;334-336.
21. Sentman C. L., Shutter J. R., Hockenbery D., Kanagawa O., Korsmeyer S. J. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 67:1991;879-888.
22. Bissonnette R. P., Echeverri F., Mahboubi A., Green D. R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature. 359:1992;552-554.
23. Miyashita T., Reed J. C. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52:1992;5407-5411.
24. Vanhacsebroek B., Reed J. C., De Valek D., Grooten J., Miyashita T., Tanaka S., Beyaert R., Van Roy F., Fiers W. Effect of bcl-2 proto-oncogene expression on cellular sensitivity to tumor necrosis factor-mediated cytotoxicity. Oncogene. 8:1993;1075-1081.
25. Itoh N., Tsujimoto Y., Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol. 151:1993;621-627.
26. 2. Oncogene. 10:1995;2297-2305.
27. Robertson J. D., Datta K., Kehrer J. P. Bcl-xL overexpression restricts heat-induced apoptosis and influences hsp70, bcl-2, and Bax protein levels in FL5.12 cells. Biochem. Biophys. Res. Commun. 241:1997;164-168.
28. Foghsgaard L., Jäättelä M. The ability of BHRF1 to inhibit apoptosis is dependent on stimulus and cell type. J. Virol. 71:1997;7509-7517.
29. Chao D. T., Korsmeyer S. J. BCl-2 family: regulators of cell death. Annu. Rev. Immunol. 16:1998;395-419.
30. Zamzami N., Brenner C., Marzo I., Susin S. A., Kroemer G. Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene. 16:1998;2265-2282.
31. Reed J. C. Bcl-2 family proteins. Oncogene. 17:1998;3225-3236.
32. Minn A. J., Kettlun C. S., Liang H., Kelekar A., Vander Heiden M. G., Chang B. S., Fesik S. W., Fill M., Thompson C. B. Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms. EMBO J. 18:1999;632-643.
33. Akao Y., Otsuki Y. S., Kataoka S., Ito Y., Tsujimoto Y. Multiple subcellular localization of bcl-2: detection in nuclear outer membrane, endoplasmic reticulum, and mitochondrial membrane. Cancer Res. 54:1994;2468-2471.
34. Zhu W., Cowie A., Wasfy G. W., Penn L. Z., Leber B., Andrews D. W. Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types. EMBO J. 15:1996;4130-4141.
35. Kluck R. M., Bossy-Wetzel E., Green D. R., Newmeyer D. D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 275:1997;1132-1136.
36. Yang J., Liu X., Bhalla K., Kim C. N., Ibrado A. M., Cai J., Peng T.-I., Jones D. P., Wang X. Prevention of apoptosis by Bcl-2: Release of cytochromec. Science. 275:1997;1129-1132.
37. L. Nature. 385:1997;353-357.
38. Schendel S. L., Xie Z., Montal M. O., Matsuyama S., Montal M., Reed J. C. Channel formation by antiapoptotic protein Bcl-2. Proc. Natl. Acad. Sci. USA. 94:1997;5113-5118.
39. Narita M., Shimizu S., Ito T., Chittenden T., Lutz R. J., Matsuda H., Tsujimoto Y. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc. Natl. Acad. Sci. USA. 95:1998;14681-14686.
40. Vander Heiden M. G., Chandel N. S., Schumacker P. T., Thompson C. B. Bcl-xL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. Mol. Cell. 3:1999;159-167.
41. He H., Lam M., McCormick T. S., Distelhorst C. W. Maintenance of calcium homeostasis in the endoplasmic reticulum by Bcl-2. J. Cell Biol. 138:1998;1219-1228.
42. Kuo T. H., Kim H. R., Zhu L., Yu Y., Lin H. M., Tsang W. Modulation of endoplasmic reticulum calcium pump by Bcl-2. Oncogene. 17:1998;1903-1910.
43. Rossé T., Olivier R., Monney L., Rager M., Conus S., Fellay I., Jansen B., Borner C. Bcl-2 prolongs cell survival after Bax-induced release of cytochromec. Nature. 391:1998;496-499.
44. Pan G., O'Rourke K., Dixit V. M. Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J. Biol. Chem. 273:1998;5841-5845.
45. Hu Y., Benedict M. A., Wu D., Inohara N., Nunez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc. Natl. Acad. Sci. USA. 95:1998;4386-4391.
46. Song Q., Kuang Y., Dixit V. M., Vincenz C. Boo, a novel negative regulator of cell death, interacts with Apaf-1. EMBO J. 18:1999;167-178.
47. Inohara N., Gourley T. S., Carrio R., Muniz M., Merino J., Garcia I., Koseki T., Hu Y., Chen S., Nunez G. Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death. J. Biol. Chem. 273:1998;32479-32486.
48. Pezzella F., Tse A. G., Cordell J. L., Pulford K. A., Gatter K. C., Mason D. Y. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am. J. Pathol. 137:1990;225-232.
49. Zutter M., Hockenbery D., Silverman G. A., Korsmeyer S. J. Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms. Blood. 78:1991;1062-1068.
50. McDonnell T. J., Troncoso P., Brisbay S. M., Logothetis C., Chung L. W., Hsieh J. T., Tu S. M., Campbell M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52:1992;6940-6944.
51. Pezzella F., Turley H., Kuzu I., Tungekar M. F., Dunnill M. S., Pierce C. B., Harris A., Gatter K. C., Mason D. Y. bcl-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med. 329:1993;690-694.
52. Leek R. D., Kaklamanis L., Pezzella F., Gatter K. C., Harris A. L. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer. 69:1994;135-139.
53. Ikegaki N., Katsumata M., Minna J., Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res. 54:1994;6-8.
54. Hague A., Moorghen M., Hicks D., Chapman M., Paraskeva C. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene. 9:1994;3367-3370.
55. Watson A. J., Merritt A. J., Jones L. S., Askew J. N., Anderson E., Becciolini A., Balzi M., Potten C. S., Hickman J. A. Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br. J. Cancer. 73:1996;889-895.
56. Reed J. C. Bcl-2 family proteins: Role in dysregulation of apoptosis and chemoresistance in cancer. Apoptosis and Cancer. 1997;Karger Landes Systems, Basel.
57. Hill M. E., MacLennan K. A., Cunningham D. C., Vaughan Hudson B., Burke M., Clarke P., Di Stefano F., Anderson L., Vaughan Hudson G., Mason D., Selby P., Linch D. C. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation Study. Blood. 88:1996;1046-1051.
58. Hermine O., Haioun C., Lepage E., d'Agay M. F., Briere J., Lavignac C., Fillet G., Salles G., Marolleau J. P., Diebold J., Reyas F., Gaulard P. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 87:1996;265-272.
59. Winter J. N., Andersen J., Reed J. C., Krajewski S., Variakojis D., Bauer K. D., Fisher R. I., Gordon L. I., Oken M. M., Jiang S., Jeffries D., Domer P. BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. Blood. 91:1998;1391-1398.
60. Campos L., Rouault J. P., Sabido O., Oriol P., Roubi N., Vasselon C., Archimbaud E., Magaud J. P., Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:1993;3091-3096.
61. Lohri A., van Hille B., Bacchi M., Fopp M., Joncourt F., Reuter J., Cerny T., Fey M. F., Herrmann R. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S. Eur. J. Haematol. 59:1997;206-215.
62. Lauria F., Raspadori D., Rondelli D., Ventura M. A., Fiacchini M., Visani G., Forconi F., Tura S. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia. 11:1997;2075-2078.
63. Kasimir-Bauer S., Ottinger H., Mousors P., Beelen D. W., Brittinger G., Seeber S., Scheulen M. E. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy. Exp. Hematol. 26:1998;1111-1117.
64. Kaufmann S. H., Karp J. E., Svingen P. A., Krajowski S., Burke P. J., Gore S. D., Reed J. C. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood. 91:1998;991-1000.
65. Robertson L. E., Plunkett W., McConnell K., Keating M. J., McDonnell T. J. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 10:1996;456-459.
66. Agular-Santelises M., Rottenberg M. E., Lewin N., Mellstedt H., Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int. J. Cancer. 69:1996;114-119.
67. Mustonen M., Raunio H., Paakko P., Soini Y. The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions. Histopathology. 31:1997;347-354.
68. Joensuu H., Pylkkanen L., Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol. 145:1994;1191-1198.
69. Silvestrini R., Veneroni S., Daidone M. G., Benini E., Boracchi P., Mezzetti M., Di Fronzo G., Rilke F., Veronesi U. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst. 86:1994;499-504.
70. Hurlimann J., Larrinaga B., Vala D. L. bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch. 426:1995;163-168.
71. Gee J. M., Robertson J. F., Ellis I. O., Willsher P., McClelland R. A., Hoyle H. B., Kyme S. R., Finlay P., Blarney R. W., Nicholson R. I. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer. 59:1994;619-628.
72. Gasparini G., Barbareschi M., Doglioni C., Palma P. D., Mauri F. A., Boracchi P., Bevilacqua P., Caffo O., Morelli L., Verderio P. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res. 1:1995;189-198.
73. Sierra A., Lloveras B., Castellsague X., Moreno L., Garcia-Ramirez M., Fabra A. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int. J. Cancer. 60:1995;54-60.
74. Sinicrope F. A., Hart J., Michelassi F., Lee J. J. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin. Cancer Res. 1:1995;1103-1110.
75. Ofner D., Riehemann K., Maier H., Riedmann B., Nehoda H., Totsch M., Bocker W., Jasani B., Schmid K. W. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br. J. Cancer. 72:1995;981-985.
76. Baretton G. B., Diebold J., Christoforis G., Vogt M., Muller C., Dopfer K., Schneiderbanger K., Schmidt M., Lohrs U. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer. 77:1996;255-264.
77. Lipponen P., Eskelinen M., Syrjanen K. Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br. J. Cancer. 71:1995;863-867.
78. Herod J. J., Eliopoulos A. G., Warwick J., Niedobitek G., Young L. S., Kerr D. J. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 56:1996;2178-2184.
79. Sinicrope F. A., Evans D. B., Leach S. D., Cleary K. R., Fenoglio C. J., Lee J. J., Abbruzzese J. L. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: Association with clinical outcome. Clin. Cancer Res. 2:1996;2015-2022.
80. Inada T., Kikuyama S., Ichikawa A., Igarashi S., Ogata Y. Bcl-2 expression as a prognostic factor of survival of gastric carcinoma. Anticancer Res. 18:1998;2003-2010.
81. Giatromanolaki A., Sivridis E., Koukourakis M. I., Harris A. L., Gatter K. C. Bcl-2 and p53 expression in stage I endometrial carcinoma. Anti-cancer Res. 18:1998;3689-3693.
82. Athanassiadou P., Petrakakou E., Sakelariou V., Zerva C., Liosi A., Michalas S., Athanassiades P. Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumors. Eur. J. Cancer Prev. 7:1998;225-231.
83. Tjalma W., Weyler J., Goovaerts G., De Pooter C., Van Marck E., van Dam P. Prognostic value of bcl-2 expression in patients with operable carcinoma of the uterine cervix. J. Clin. Pathol. 50:1997;33-36.
84. Marx D., Binder C., Meden H., Lenthe T., Ziemek T., Hiddemann T., Kuhn W., Schauer A. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res. 17:1997;2233-2240.
85. Fontanini G., Vignati S., Bigini D., Mussi A., Lucchi M., Angeletti C. A., Basolo F., Bevilacqua G. Bcl-2 protein: A prognostic factor inversely correlated to p53 in non- small-cell lung cancer. Br. J. Cancer. 71:1995;1003-1007.
86. Anton R. C., Brown R. W., Younes M., Gondo M. M., Stephenson M. A., Cagle P. T. Absence of prognostic significance of bcl-2 immunopositivity in non- small cell lung cancer: Analysis of 427 cases. Hum. Pathol. 28:1997;1079-1082.
87. Bubendorf L., Sauter G., Moch H., Jordan P., Blochlinger A., Gasser T. C., Mihatsch M. J. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am. J. Pathol. 148:1996;1557-1565.
88. Bauer J. J., Sesterhenn I. A., Mostofi F. K., McLeod D. G., Srivastava S., Moul J. W. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol. 156:1996;1511-1516.
89. Apakama I., Robinson M. C., Walter N. M., Charlton R. G., Royds J. A., Fuller C. E., Neal D. E., Hamdy F. C. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br. J. Cancer. 74:1996;1258-1262.
90. Eid H., Gulyas M., Geczi L., Bodrogi I., Institoris E., Bak M. Expression of bcl-2 in testicular carcinoma: Correlation with tumor progression and MDR1/Pgp. Cancer. 83:1998;331-336.
91. Grover R., Wilson G. D. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur. J. Surg. Oncol. 22:1996;347-349.
92. Castle V. P., Heidelberger K. P., Bromberg J., Ou X., Dole M., Nunez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am. J. Pathol. 143:1993;1543-1550.
93. Ikeda H., Hirato J., Akami M., Matsuyama S., Suzuki N., Takahashi A., Kuroiwa M. Bcl-2 oncoprotein expression and apoptosis in neuroblastoma. J. Pediatr. Surg. 30:1995;805-808.
94. Meijerink J. P., Mensink E. J., Wang K., Sedlak T. W., Sloetjes A. W., de Witte T., Waksman G., Korsmeyer S. J. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood. 91:1998;2991-2997.
95. Stoetzer O. J., Nussler V., Darsow M., Gullis E., Pelka-Fleischer R., Scheel U., Wilmanns W. Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia. 10:1996;S18-S22.
96. Friess H., Lu Z., Graber H. U., Zimmermann A., Adler G., Korc M., Schmid R. M., Buchler M. W. bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut. 43:1998;414-421.
97. Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V. M., Niskanen E., Nordling S., Reed J. C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55:1995;4471-4478.
98. Nakara B., Muguruma K., Hirakawa K., Chung Y. S., Yamashita Y., Inoue T., Matsuoka T., Onoda N., Kato Y., Sowa M. Predictive value of Bcl-2 and Bax protein expression for chemotherapeutic effect in gastric cancer. A pilot study. Oncology. 55:1998;543-547.
99. Ogura E., Senzaki H., Yamamoto D., Yoshida R., Takada H., Hioki K., Tsubura A. Prognostic significance of Bcl-2, Bcl-xL/S, Bax and Bak expressions in colorectal carcinomas. Oncol. Rep. 6:1999;365-369.
100. Ouyang H., Furukawa T., Abe T., Kato Y., Horii A. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin. Cancer Res. 4:1998;1071-1074.
101. Crawford R. A., Caldwell C., Iles R. K., Lowe D., Shepherd J. H., Chard T. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br. J. Cancer. 78:1998;210-214.
102. Huang D. C. S., O'Reilly L. A., Strasser A., Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J. 16:1997;4628-4638.
103. Olopade O. I., Adeyanju M. O., Safa A. R., Hagos F., Mick R., Thompson C. B., Recant W. M. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J. Sci. Am. 3:1997;230-237.
104. Ciocca D. R., Clark G. M., Tandon A. K., Fuqua S. A., Welch W. J., McGuire W. L. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: Prognostic implications. J. Natl. Cancer Inst. 85:1993;570-574.
105. Lindquist S., Craig E. A. The heat shock proteins. Annu. Rev. Genet. 22:1988;631-677.
106. McKay D. B. Structure and mechanism of 70-kDa heat-shock-related proteins. Adv. Protein Chem. 44:1993;67-97.
107. Arrigo A. P. Small stress proteins: Chaperones that act as regulators of intracellular redox state and programmed cell death. Biol. Chem. 379:1998;19-26.
108. Bukau B., Horwich A. L. The IIsp70 and Hsp60 chaperone machines. Cell. 92:1998;351-366.
109. Landry J., Bernie R. D., Chértien P., Nicole L. M., Tanguay R. M., Marceau N. Synthesis and degradation of heat shock proteins during development and decay of thermotolerance. Cancer Res. 42:1982;2457-2461.
110. Jonston R. N., Kucey B. L. Competitive inhibition of hsp70 gene expression causes thermosensitivity. Science. 242:1988;1551-1554.
111. Riabolow K. T., Mizzen L. A., Welch W. J. Heat shock is lethal to fibroblasts microinjected with antibodies against hsp70. Science. 242:1988;433-436.
112. Li G. C., Li L., Liu Y.-K., Mak J. Y., Chen L., Lee W. M. F. Thermal response of rat fibroblasts stably transfected with the human 70-kDa heat shock protein-encoding gene. Proc. Natl. Acad. Sci. USA. 88:1991;1681-1685.
113. Landry J., Crétien P., Lambert H., Hickey E. Heat shock resistance conferred by expression of the human HSP27 gene in rodent cells. J. Cell Biol. 109:1989;7-15.
114. Jäättelä M., Wissing D. Heat shock proteins protect cells from monocyte cytotoxicity: possible mechanism of self-protection. J. Exp. Med. 177:1993;231-236.
115. Karlseder J., Wissing D., Holzer G., Orel L., Sliotz G., Auer H., Jäättelä M., Simon M. M. Hsp70 overexpression mediates the escape of a doxorubicin-induced G2 cell cycle arrest. Biochem. Biophys. Res. Commun. 220:1996;153-159.
116. Simon M. M., Krone C., Schwarz A., Luger T. A., Jäättelä M., Schwarz T. Heat shock protein 70 overexpression affects the response to ultraviolet light in murine fibroblasts. Evidence for increased cell viability and suppression of cytokine release. J. Clin. Invest. 95:1995;926-933.
117. Bellmann K., Jäättelä M., Wissing D., Burkart V., Kolb H. Heat shock protein Hsp70 overexpression confers resistance against nitric oxide. FEBS Lett. 391:1996;185-188.
118. Samali A., Cotter T. G. Heat shock proteins increase resistance to apoptosis. Exp. Cell Res. 223:1996;163-170.
119. Kwak H. J., Jun C. D., Pac H. O., Yoo J. C., Choi B. M., Na Y. G., Park R. K., Chung H. T., Chung H. Y., Park W. Y., Seo J. S. The role of inducible 70-kDa heat shock protein in cell cycle control, differentiation, and apoptotic cell death of the human myeloid leukemic HL-60 cells. Cell. Immunol. 187:1998;1-12.
120. Liossis S. N., Ding X. Z., Kiang J. G., Tsokos G. C. Overexpression of the heat shock protein 70 enhances the TCR/CD3- and Fas/Apo-1/CD95-mediated apoptotic cell death in Jurkat T cells. J. Immunol. 158:1997;5668-5675.
121. Multhoff G., Botzler C., Jennen L., Schmidt J., Ellwart J., Issels R. Heat shock protein 72 on tumor cells: A recognition structure for natural killer cells. J. Immunol. 158:1997;4341-4350.
122. Richards E. H., Hickey E., Weber L., Master J. R. Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res. 56:1996;2446-2451.
123. Trautinger F., Kokesch C., Herbacek I., Knobler R. M., Kindas-Mugge I. Overexpression of the small heat shock protein, hsp27, confers resistance to hyperthermia, but not to oxidative stress and UV-induced cell death, in a stably transfected squamous cell carcinoma cell line. J. Photochem. Photobiol. B 39:1997;90-95.
124. Freeman B. C., Myers M. P., Schumacher R., Morimoto R. I. Identification of a regulatory motif in Hsp70 that affects ATPase activity, substrate binding and interaction with HDJ-1. EMBO J. 14:1995;2281-2292.
125. Nollen E. A., Brunsting J. F., Roelofsen H., Weber L. A., Kampinga H. H. In vivo chaperone activity of heat shock protein 70 and thermotolerance [in press citation]. Mol. Cell Biol. 19:1999;2069-2079.
126. Li G. C., Li L., Liu R. Y., Rehman M., Lee W. M. F. Protection from thermal stress by human hsp70 with or without its ATP-binding domain. Proc. Natl. Acad. Sci. USA. 89:1992;2036-2040.
127. Stürzbecher H.-W., Addison, Jenkins J. R. Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells. Mol. Cell. Biol. 8:1988;3740-3747.
128. Koskinen P., Sistonen L., Evan G., Morimoto R., Alitalo K. Nuclear colocalization of cellular and viral myc proteins with HSP70 in myc-overexpressing cells. J. Virol. 65:1991;842-851.
129. Takayama S., Xie Z., Reed J. C. An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators. J. Biol. Chem. 274:1999;781-786.
130. Mehlen P., Kretz-REmy C., Préville X., Arrigo A.-P. Human hsp27,Drosophila. EMBO J. 15:1996;2695-2706.
131. Préville X., Salvemini F., Giraud S., Chaufour S., Paul C., Stepien G., Ursini M. V., Arrigo A. P. Mammalian small stress proteins protect against oxidative stress through their ability to increase glucose-6-phosphate dehydrogenase activity and by maintaining optimal cellular detoxifying machinery. Exp. Cell Res. 247:1999;61-78.
132. Jäättelä M. Overexpression of hsp70 confers tumorigenicity to mouse fibrosarcoma cells. Int. J. Cancer. 60:1995;689-693.
133. Garrido C., Fromentin A., Bonnotte B., Favre N., Moutet M., Arrigo A. P., Mehlen P., Solary E. Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res. 58:1998;5495-5499.
134. Lemieux P., Oesterreich S., Lawrence J. A., Steeg P. S., Hilsenbeck S. G., Harvey J. M., Fuqua S. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis. 17:1997;113-123.
135. Soo J. S., Park Y. M., Kim J. I., Shim E. H., Kim C. W., Jang J. J., Kim S. H., Lee W. H. T cell lymphoma in transgenic mice expressing the human hsp70 gene. Biochem. Biophys. Res. Comm. 218:1996;582-587.
136. r. Clin. Cancer Res. 1:1995;1217-1222.
137. Lazaris A. C., Theodoropoulos G. E., Aroni K., Saetta A., Davaris P. S. Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch. 426:1995;461-467.
138. Kaur J., Ralhan R. Differential expression of 70-kDa heat shock protein in human oral tumorigenesis. Int. J. Cancer. 63:1995;774-779.
139. Chant I. D., Rose P. E., Morris A. G. Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. Br. J. Haematol. 90:1995;163-168.
140. Santarosa M., Favaro D., Quaia M., Galligioni E. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur. J. Cancer. 33:1997;873-877.
141. Lazaris A. C., Chatzigianni E. B., Panoussopoulos D., Tzimas G. N., Davaris P. S., Golematis B. C. Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified. Breast Cancer Res. Treat. 43:1997;43-51.
142. Trieb K., Lochleitner T., Lang S., Windhager R., Kotz R., Dirnhofer S. Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy. Hum. Pathol. 29:1998;1050-1055.
143. Vargas-Roig L. M., Fanelli M. A., Lopez L. A., Gago F. E., Tello O., Aznar J. C., Ciocca D. R. Heat shock proteins and cell proliferation in human breast cancer biopsy samples. Cancer Detect. Prev. 21:1997;441-451.
144. Vargas-Roig L. M., Gago F. E., Tello O., Aznar J. C., Ciocca D. R. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int. J. Cancer. 73:1998;468-475.
145. Liu F. F., Miller N., Levin W., Zanke B., Cooper B., Henry M., Sherar M. D., Pintillie M., Hunt J. W., Hill R. P. The potential role of HSP70 as an indicator of response to radiation and hyperthermia treatments for recurrent breast cancer [see comments]. Int. J. Hyperthermia. 12:1996;197-208.
146. Ciocca D. R., Green S., Elledge R. M., Clark G. M., Pugh R., Ravdin P., Lew D., Martino S., Osborne C. K. Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study). Clin. Cancer Res. 4:1998;1263-1266.
147. Nanbu K., Konishi I., Mandai M., Kuroda H., Hamid A. A., Komatsu T., Mori T. Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas [in press citation]. Cancer Detect. Prev. 22:1998;549-555.
148. Ciocca D. R., Oesterreich S., Chamness G. C., McGuire W. L., Fuqua S. A. Biological and clinical implications of heat shock protein 27,000 (Hsp27): A review. J. Natl. Cancer Inst. 85:1993;1558-1570.
149. Ciocca D. R., Luque E. H. Immunological evidence for the identity between the hsp27 estrogen-regulated heat shock protein and the p29 estrogen receptor-associated protein in breast and endometrial cancer. Breast Cancer Res. Treat. 20:1991;33-42.
150. Hurlimann J., Gebhard S., Gomez F. Oostrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology. 23:1993;239-248.
151. Oesterreich S., Hilsenbeck S. G., Ciocca D. R., Allred D. C., Clark G. M., Chamness G. C., Osborne C. K., Fuqua S. A. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin. Cancer Res. 2:1996;1199-1206.
152. Love S., King R. J. A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br. J. Cancer. 69:1994;743-748.
153. Devaja O., King R. J., Papadopoulos A., Raju K. S. Heat-shock protein 27 (HSP27) and its role in female reproductive organs. Eur. J. Gynaecol. Oncol. 18:1997;16-22.
154. Ungar D. R., Hailat N., Strahler J. R., Kuick R. D., Brodeur G. M., Seeger R. C., Reynolds C. P., Hanash S. M. Hsp27 expression in neuroblastoma: Correlation with disease stage. J. Natl. Cancer Inst. 86:1994;780-784.
155. Khalid H., Tsutsumi K., Yamashita H., Kishikawa M., Yasunaga A., Shibata S. Expression of the small heat shock protein (hsp) 27 in human astrocytomas correlates with histologic grades and tumor growth fractions. Cell. Mol. Neurobiol. 15:1995;257-268.
156. Hitotsumatsu T., Iwaki T., Fukui M., Tateishi J. Distinctive immunohistochemical profiles of small heat shock proteins (heat shock protein 27 and alpha B-crystallin) in human brain tumors. Cancer. 77:1996;352-361.
157. Takashi M., Sakata T., Ohmura M., Kato K. Elevated concentrations of the small stress protein HSP27 in rat renal tumors. Urol. Res. 25:1997;173-177.
158. Ito T., Kawabe R., Kurasono Y., Hara M., Kitamura H., Fujita K., Kanisawa M. Expression of heat shock proteins in squamous cell carcinoma of the tongue: An immunohistochemical study. J. Oral Pathol. Med. 27:1998;18-22.
159. Langdon S. P., Rabiasz G. J., Hirst G. L., King R. J., Hawkins R. A., Smyth J. F., Miller W. R. Expression of the heat shock protein HSP27 in human ovarian cancer. Clin. Cancer Res. 1:1995;1603-1609.
160. Uozaki H., Horiuchi H., Ishida T., Iijima T., Imamura T., Machinami R. Overexpression of resistance-related proteins (metallothioneins, glutathione-S. Cancer. 79:1997;2336-2344.
161. Crook N. E., Clem R. J., Miller L. K. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J. Virol. 67:1993;2168-2174.
162. Birnbaum M. J., Clem R. J., Miller L. K. An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J. Virol. 68:1994;2521-2528.
163. Deveraux Q. L., Reed J. C. IAP family proteins - Suppressors of apoptosis. Genes Dev. 13:1999;239-252.
164. Deveraux Q. L., Takahashi R., Salvesen G. S., Reed J. C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 388:1997;300-304.
165. Roy N., Deveraux Q. L., Takahashi R., Salvesen G. S., Reed J. C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16:1997;6914-6925.
166. Tamm I., Wang Y., Sausville E., Scudiero D. A., Vigna N., Oltersdorf T., Reed J. C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:1998;5315-5320.
167. Deveraux Q. L., Roy N., Stennicke H. R., Van Arsdale T., Zhou Q., Srinivasula S. M., Alnemri E. S., Salvesen G. S., Reed J. C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17:1998;2215-2223.
168. Rothe M., Pan M.-G., Henzel W. J., Ayers T. M., Goeddel D. V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculovirus inhibitor of apoptosis proteins. Cell. 83:1995;1243-1252.
169. Li F., Ambrosini G., Chu E. Y., Plescia J., Tognin S., Marchisio P. C., Altieri D. C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:1998;580-584.
170. Ambrosini G., Adida C., Altieri D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3:1997;917-921.
171. Adida C., Crotty P. L., McGrath J., Berrebi D., Diebold J., Altieri D. C. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol. 152:1998;43-49.
172. Kawasaki H., Altieri D. C., Lu C. D., Toyoda M., Tenjo T., Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58:1998;5071-5074.
173. Lu C. D., Altieri D. C., Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 58:1998;1808-1812.
174. Adida C., Berrebi D., Peuchmaur M., Reyes-Mugica M., Altieri D. C. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma [letter]. Lancet. 351:1998;882-883.
175. Bauerle P. A., Henkel T. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12:1994;141-179.
176. Beg A. A., Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science. 274:1996;782-784.
177. Wang C.-Y., Mayo M. W., Baldwin A. S. Jr. TNF- and cancer therapy-induced apoptosis potentiation by inhibition of NF-κB. Science. 274:1996;784-787.
178. Antwerp D. J., Martin S. J., Kafri T., Green D. R., Verma I. M. Suppression of TNF-α-induced apoptosis by NF-κB. Science. 274:1996;787-789.
179. Luque I., Gelinas C. Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin. Cancer Biol. 8:1997;103-111.
180. Wang C.-Y., Mayo M. W., Korneluk R. G., Goeddel D. V., Baldwin A. S. J. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and cIAP1 and cIAP2 to suppress caspase-8 activation. Science. 281:1998;1680-1683.
181. Wong G. H. W., Goeddel D. V. Induction of manganous superoxide dismutase by tumor necrosis factor: Possible protective mechanism. Science. 242:1988;941-944.
182. Jäättelä M., Mourizen H., Elling F., Bastholm L. A20 zinc finger protein inhibits TNF and IL-1 signaling. J. Immunol. 156:1996;1166-1173.
183. Wu M. X., Ao Z., Prasad K. V. S., Wu R., Schlossman S. F. IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival. Science. 281:1998;998-1001.
184. Chu Z.-L., McKinsey T. A., Liu L., Gentry J., Malim M. H., Ballard D. W. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc. Natl. Acad. Sci. USA. 94:1997;10057-10062.
185. Wei Y., Zhao X., Kariya Y., Teshigawara K., Uchida A. Inhibition of proliferation and induction of apoptosis by abrogation of heat-shock protein (HSP) expression in tumor cells. Cancer Immunol. Immunother. 40:1995;73-78.
186. Mairesse N., Horman S., Mosselmans R., Galand P. Antisense inhibition of the 27 kDa heat shock protein production affects growth rate and cytoskeletal organization in MCF-7 cells. Cell Biol. Int. 20:1996;205-212.
187. Ambrosini G., Adida C., Sirugo G., Altieri D. C. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J. Biol. Chem. 273:1998;11177-11182.
188. Reed J. C. Promise and problems of Bcl-2 antisense therapy [editorial; comment]. J. Natl. Cancer Inst. 89:1997;988-990.
189. Webb A., Cunningham D., Cotter F., Clarke P. A., di Stefano F., Ross P., Corbo M., Dzicwanowska Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 349:1997;1137-1141.